| Failure of atorvastatin to modulate CSF HIV-1 infection: results of a pilot study. | |
| | |
MedLine Citation:
|
PMID: 18695163 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: HIV-1 infection of the CSF space is nearly universal in untreated systemic infection, and correlates strongly with intrathecal and systemic immunoactivation and CSF pleocytosis. Based on the potential immunomodulatory and antiviral properties of HMG-CoA reductase inhibitors (statins), we examined the effect of atorvastatin on CSF HIV-1 infection and associated CSF abnormalities in a small pilot study. METHODS: Seven male HIV-1-infected, antiretroviral-naïve subjects with a mean blood CD4+ T cell count of 473 cells/muL were studied in an open-label, single-arm pilot study to assess the effects of 80 mg atorvastatin daily for 8 weeks. The primary endpoint was the change in CSF HIV-1 RNA levels, both absolutely and relative to plasma HIV-1 RNA, at 4 and 8 weeks of treatment. Other outcome measures included CSF white blood cell counts and neopterin concentrations as indices of intrathecal immunoactivation, and blood HIV-1 RNA levels, neopterin concentrations, and T lymphocyte counts. Effects on blood lipids were used to monitor the established biologic effects of atorvastatin and treatment adherence. RESULTS: No significant changes in CSF virologic and inflammatory indices or in systemic HIV-1 infection were observed during atorvastatin treatment despite potent reduction of blood lipids. CONCLUSION: Atorvastatin showed no appreciable effect on CSF HIV-1 infection or intrathecal immunoactivation in this small uncontrolled study and thus appears to have little promise as an immunomodulatory adjuvant therapy for CNS HIV-1 infection, at least in neuroasymptomatic subjects with preserved CD4+ T cell counts. |
| | |
Authors:
|
J C Probasco; S S Spudich; J Critchfield; E Lee; N Lollo; S G Deeks; R W Price |
Related Documents
:
|
16868533 - Treatment of infection with radiolabeled antibodies. 2573513 - Human herpes virus-6 increases hiv-1 expression in co-infected t cells via nuclear fact... 3535213 - Urinary tract infections in compromised hosts. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Neurology Volume: 71 ISSN: 1526-632X ISO Abbreviation: Neurology Publication Date: 2008 Aug |
Date Detail:
|
Created Date: 2008-08-12 Completed Date: 2008-10-14 Revised Date: 2009-11-18 |
Medline Journal Info:
|
Nlm Unique ID: 0401060 Medline TA: Neurology Country: United States |
Other Details:
|
Languages: eng Pagination: 521-4 Citation Subset: AIM; IM |
Affiliation:
|
Department of Neurology, University of California San Francisco, CA, USA. rwprice@sfgh.ucsf.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Anti-HIV Agents / therapeutic use* CD4 Lymphocyte Count CD4-Positive T-Lymphocytes / drug effects CD8-Positive T-Lymphocytes / drug effects HIV Infections / cerebrospinal fluid*, drug therapy* HIV-1 / drug effects* Heptanoic Acids / therapeutic use* Humans Male Neopterin / blood Pilot Projects Pyrroles / therapeutic use* Viral Load |
| Grant Support | |
ID/Acronym/Agency:
|
K23 MH074466/MH/NIMH NIH HHS; R01 MH62701/MH/NIMH NIH HHS; UL1 RR024131/RR/NCRR NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Anti-HIV Agents; 0/Heptanoic Acids; 0/Pyrroles; 110862-48-1/atorvastatin; 670-65-5/Neopterin |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Association of paraoxonase gene cluster polymorphisms with ALS in France, Quebec, and Sweden.
Next Document: Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures.